Parathyroid hormone levels do not determine risk of hyperparathyroidism complications
Parathyroid hormone levels of patients with primary hyperparathyroidism are not predictive of kidney stones or low bone density, according to research published inThe Journal of Clinical Endocrinology& Metabolism.Healio (Source: Society for Endocrinology)
Source: Society for Endocrinology - April 5, 2019 Category: Endocrinology Source Type: news

Parathyroid Hormone Replacement Effective, Safe Long Term Parathyroid Hormone Replacement Effective, Safe Long Term
A 6-year open-label extension study of recombinant human parathyroid hormone shows efficacy, safety in treating chronic hyperparathyroidism.Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - April 4, 2019 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news

Intraoperative Parathyroid Monitoring in Hyperparathyroidism Intraoperative Parathyroid Monitoring in Hyperparathyroidism
What are the benefits of parathyroid hormone monitoring during surgery for primary hyperparathyroidism?Clinical Endocrinology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 18, 2019 Category: Consumer Health News Tags: Diabetes & Endocrinology Journal Article Source Type: news

UCLA receives $15.2 million bequest from estate of entertainer Garry Shandling
A bequest of $15.2 million from the estate of entertainer Garry Shandling will advance research in several fields at theDavid Geffen School of Medicine at UCLA.Shandling, the comedian, actor, director, writer  and producer who died in March 2016, earmarked the funds to benefit three units — the division of endocrinology, diabetes and hypertension; the division of infectious diseases; and the UCLA Agi Hirshberg Center for Pancreatic Diseases — as well as general medical research at the David Geffen S chool of Medicine, establishing a meaningful philanthropic legacy.His gift will establish and endow the Garr...
Source: UCLA Newsroom: Health Sciences - February 5, 2019 Category: Universities & Medical Training Source Type: news

Active Vitamin D No Help for CV Events in Select CKD Patients (CME/CE)
(MedPage Today) -- Oral alfacalcidol flops in dialysis patients without secondary hyperparathyroidism (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - December 19, 2018 Category: Cardiology Source Type: news

Alfacalcidol Does Not Lower CV Risk in Dialysis, Trial Suggests Alfacalcidol Does Not Lower CV Risk in Dialysis, Trial Suggests
Alfacalcidol did not reduce the risk for cardiovascular events in patients without secondary hyperparathyroidism who were undergoing maintenance hemodialysis, the J-DAVID trial found.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 14, 2018 Category: Consumer Health News Tags: Nephrology News Source Type: news

Vitamin D Analogue No Help for CV Prevention in Hemodialysis Patients
(MedPage Today) -- Trial limited to patients without secondary hyperparathyroidism (Source: MedPage Today Nephrology)
Source: MedPage Today Nephrology - December 13, 2018 Category: Urology & Nephrology Source Type: news

Amgen sues Durham generics company
California-based biopharmaceutical company Amgen (Nasdaq: AMGN) has filed a patent infringement lawsuit against growing generics company Accord Healthcare and parent company Intas Pharmaceuticals.   Amgen's lawsuit stems from Accord Healthcare's plans to manufacture and sell a generic version of Amgen's drug, Sensipar, for the management of a type of hyperparathyroidism that causes detrimentally-high levels of calcium in the body. Sensipar raked in about $1.7 billion in revenue for Amgen l ast year. According… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - July 3, 2018 Category: American Health Authors: Jennifer Henderson Source Type: news

Finding the Genetic Cause of a Form of Hyperparathyroidism
Researchers have identified genetic differences that can cause familial isolated hyperparathyroidism. (Source: NIDDK News)
Source: NIDDK News - June 23, 2018 Category: Endocrinology Source Type: news

Cholecalciferol and Hyperparathyroidism Progression in CKD Cholecalciferol and Hyperparathyroidism Progression in CKD
A new study examines the effects of a higher dose of cholecalciferol on parathyroid hormone levels in patients with CKD.Nephrology Dialysis Transplantation (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 9, 2018 Category: Consumer Health News Tags: Nephrology Journal Article Source Type: news

CDC73-Related Disorders in Primary Hyperparathyroidism CDC73-Related Disorders in Primary Hyperparathyroidism
This article provides insight into the clinical manifestations of CDC73-related disorders and discusses ways to improve case detection in primary hyperparathyroidism.Journal of Clinical Endocrinology & Metabolism (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 23, 2018 Category: Consumer Health News Tags: Diabetes & Endocrinology Journal Article Source Type: news

Amgen ’s Mimpara for secondary HPT children with ESRD receives marketing approval in EU
US-based biopharmaceutical company Amgen has been granted marketing authorisation by the European Commission (EC) for Mimpara (cinacalcet) to treat secondary hyperparathyroidism (HPT) in children with end ‑stage renal disease (ESRD). (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - September 1, 2017 Category: Pharmaceuticals Source Type: news

European Commission Approves Expanded Use Of Mimpara ® (Cinacalcet) For The Treatment Of Secondary Hyperparathyroidism In Children With End-Stage Renal Disease On Dialysis
THOUSAND OAKS, Calif., Aug. 31, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the European Commission (EC) has granted Marketing Authorization of a pediatric formulation (granules in capsule for opening) of Mimpara® (cinacalcet) for the treatment of secondary hyperparathyroidism (HPT) in children aged three years and older with end‑stage renal disease (ESRD) on maintenance dialysis therapy in whom secondary HPT is not adequately controlled with standard of care therapy. "Secondary HPT is a serious and complex condition, and there are currently limited treatment options available for...
Source: Amgen News Release - August 31, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Factors Affecting 4D-CT Accuracy for Hyperparathyroidism Elucidated Factors Affecting 4D-CT Accuracy for Hyperparathyroidism Elucidated
Reuters Health Information (Source: Medscape Radiology Headlines)
Source: Medscape Radiology Headlines - August 18, 2017 Category: Radiology Tags: Radiology News Source Type: news

The Often Missed Diagnosis of Primary Hyperparathyroidism The Often Missed Diagnosis of Primary Hyperparathyroidism
Dr Arefa Cassoobhoy highlights one of the week's important news stories for primary care.Medscape Internal Medicine (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 18, 2017 Category: Consumer Health News Tags: Internal Medicine Commentary Source Type: news

Widespread Underdiagnosis of Hyperparathyroidism in Hypercalcemia Widespread Underdiagnosis of Hyperparathyroidism in Hypercalcemia
Only a minority of patients with hypercalcemia are tested for hyperparathyroidism, and only a minority of those found to have hyperthyroidism receive surgical referrals, according to a new database study.Reuters Health Information (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - August 1, 2017 Category: Surgery Tags: General Surgery News Source Type: news

Amgen Receives Positive CHMP Opinion To Expand Use Of Mimpara ® (cinacalcet) For The Treatment Of Secondary Hyperparathyroidism In Certain Children With End-Stage Renal Disease On Dialysis
THOUSAND OAKS, Calif., June 23, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for the Marketing Authorization of a pediatric formulation (granules in capsule for opening) of Mimpara® (cinacalcet). Approval was recommended for the treatment of secondary hyperparathyroidism (HPT) in children aged three years and older with end‑stage renal disease (ESRD) on maintenance dialysis therapy in whom secondary HPT is not adequately controlled with standard of care therapy. &quo...
Source: Amgen News Release - June 23, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Thiazide Treatment in Primary Hyperparathyroidism Thiazide Treatment in Primary Hyperparathyroidism
Thiazides may be a safe and effective treatment alternative for patients with primary hyperparathyroidism when surgery is not an option.Journal of Clinical Endocrinology & Metabolism (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 30, 2017 Category: Consumer Health News Tags: Diabetes & Endocrinology Journal Article Source Type: news

Parathyroid Biopsy Extent Influences Gamma Probe Findings Parathyroid Biopsy Extent Influences Gamma Probe Findings
During radioguided surgery for hyperparathyroidism, a large proportion of hyperfunctional parathyroid gland must be evaluated to confirm complete excision of abnormal tissue via gamma probe, according to a retrospective review.Reuters Health Information (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 5, 2017 Category: Consumer Health News Tags: Pathology & Lab Medicine News Source Type: news

US FDA approves Amgen ’s Parsabiv to treat HPT in adult patients
The US Food and Drug Administration (FDA) has approved Amgen ’s Parsabiv (etelcalcetide) to treat secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on haemodialysis. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - February 9, 2017 Category: Pharmaceuticals Source Type: news

FDA OKs Novel Calcimimetic for Secondary Hyperparathyroidism FDA OKs Novel Calcimimetic for Secondary Hyperparathyroidism
The drug is the first approved in 12 years to treat secondary hyperparathyroidism in hemodialysis patients, and the first that can be given intravenously by a dialysis team.FDA Approvals (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - February 8, 2017 Category: Drugs & Pharmacology Tags: Nephrology News Alert Source Type: news

FDA Approves Amgen's Parsabiv (etelcalcetide) for Secondary Hyperparathyroidism in Adult Patients on Hemodialysis
THOUSAND OAKS, Calif., Feb. 7, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved Parsabiv (etelcalcetide) for the treatment of secondary hyperparathyroidism (HPT) in adult patients... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - February 8, 2017 Category: Drugs & Pharmacology Source Type: news

FDA Approves Amgen's Parsabiv(TM) (Etelcalcetide), First New Treatment In More Than A Decade For Secondary Hyperparathyroidism In Adult Patients On Hemodialysis
THOUSAND OAKS, Calif., Feb. 7, 2017 -- (Healthcare Sales & Marketing Network) -- Amgen (AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved Parsabiv™ (etelcalcetide) for the treatment of secondary hyperparathyroidism (HPT) ... Biopharmaceuticals, Endocrinology, FDA Amgen, Parsabiv, Etelcalcetide, hyperparathyroid (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - February 8, 2017 Category: Pharmaceuticals Source Type: news

FDA approves Amgen drug for secondary hyperparathyroidism
(Reuters) - The U.S. Food and Drug Administration has approved Amgen Inc's treatment for secondary hyperparathyroidism in adult patients with chronic kidney disease undergoing dialysis, the U.S. biotech company said on Tuesday. (Source: Reuters: Health)
Source: Reuters: Health - February 8, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

FDA Approves Amgen's Parsabiv ™ (Etelcalcetide), First New Treatment In More Than A Decade For Secondary Hyperparathyroidism In Adult Patients On Hemodialysis
Intravenous Administration Puts Delivery in Hands of Healthcare Provider THOUSAND OAKS, Calif., Feb. 7, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved Parsabiv™ (etelcalcetide) for the treatment of secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on hemodialysis. Parsabiv is the first therapy approved for this condition in 12 years and the only calcimimetic that can be administered intravenously by the dialysis health care team three times a week at the end of the hemodialysis session. To view ...
Source: Amgen News Release - February 8, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Study Results Published in the Journal of the American Medical Association Show Amgen's Parsabiv(TM) (Etelcalcetide) Significantly Reduced Serum Parathyroid Hormone in Adults With Secondary Hyperparathyroidism on Hemodialysis
THOUSAND OAKS, Calif., Jan. 10, 2017 -- (Healthcare Sales & Marketing Network) -- Amgen (AMGN) today announced the Journal of the American Medical Association (JAMA) publication of findings from three Phase 3 studies of Parsabiv™ (etelcalcetide), an inves... Biopharmaceuticals Amgen, Parsabiv, etelcalcetide, hyperparathyroidism (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - January 11, 2017 Category: Pharmaceuticals Source Type: news

Study Results Published in the Journal of the American Medical Association Show Amgen's Parsabiv ™ (Etelcalcetide) Significantly Reduced Serum Parathyroid Hormone in Adults With Secondary Hyperparathyroidism on Hemodialysis
THOUSAND OAKS, Calif., Jan. 10, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the Journal of the American Medical Association (JAMA) publication of findings from three Phase 3 studies of Parsabiv™ (etelcalcetide), an investigational intravenous calcimimetic agent in the U.S. The studies evaluated Parsabiv in more than 1,700 adults with secondary hyperparathyroidism (sHPT) on hemodialysis and showed that the drug produced statistically significant and clinically meaningful reductions in serum parathyroid hormone (PTH) levels, a key marker of sHPT. sHPT is a chronic and serious condition that is often p...
Source: Amgen News Release - January 10, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Calcimimetic Promising for Hyperparathyroidism in ESRD (CME/CE)
(MedPage Today) -- GI adverse events still a problem for patients on hemodialysis (Source: MedPage Today Nephrology)
Source: MedPage Today Nephrology - January 10, 2017 Category: Urology & Nephrology Source Type: news

Hyperparathyroidism
Title: HyperparathyroidismCategory: Diseases and ConditionsCreated: 12/31/1997 12:00:00 AMLast Editorial Review: 1/4/2017 12:00:00 AM (Source: MedicineNet Thyroid General)
Source: MedicineNet Thyroid General - January 4, 2017 Category: Endocrinology Source Type: news

Thiazides may be safe choice for hypercalciuria in hyperparathyroidism Thiazides may be safe choice for hypercalciuria in hyperparathyroidism
In nonoperable patients with symptomatic primary hyperparathyroidism (PHPT), thiazides may be used to treat hypercalciuria without significantly exacerbating hypercalcemia, a retrospective study suggests.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 3, 2017 Category: Consumer Health News Tags: Urology News Source Type: news

European Commission Approves Parsabiv ™ (etelcalcetide) For The Treatment Of Secondary Hyperparathyroidism In Adults On Hemodialysis
First Treatment Advance for Secondary Hyperparathyroidism in More Than a Decade and First Intravenous Calcimimetic to Help Healthcare Providers Lower Key Lab Values THOUSAND OAKS, Calif., Nov. 11, 2016 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the European Commission (EC) has granted marketing authorization for Parsabiv™ (etelcalcetide) for the treatment of secondary hyperparathyroidism (sHPT) in adult patients with chronic kidney disease (CKD) on hemodialysis. Parsabiv is the first calcimimetic agent that can be administered intravenously by a healthcare provider three times a week at the en...
Source: Amgen News Release - November 11, 2016 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Mayo Clinic PathWays: What's the diagnosis?
  This week's case is that of a 68-year-old woman with a diagnosis of primary hyperparathyroidism. The patient underwent right superior parathyroid gland resection and experienced prolonged paralysis and apnea post-surgery. What was the reason for this result? View the case and make your diagnosis. Learn more about Mayo Clinic PathWays. (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - November 2, 2016 Category: Databases & Libraries Source Type: news

Amgen Provides Update On Status Of Parsabiv(TM) (Etelcalcetide) New Drug Application (NDA) Submitted To The U.S. Food And Drug Administration (FDA)
THOUSAND OAKS, Calif., Aug. 24, 2016 -- (Healthcare Sales & Marketing Network) -- Amgen (AMGN) today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter for the New Drug Application (NDA) for Parsabiv™ (etelcal... Biopharmaceuticals, FDA Amgen, Parsabiv, Etelcalcetide, hyperparathyroid (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - August 25, 2016 Category: Pharmaceuticals Source Type: news

Amgen Provides Update On Status Of Parsabiv ™ (Etelcalcetide) New Drug Application (NDA) Submitted To The U.S. Food And Drug Administration (FDA)
THOUSAND OAKS, Calif., Aug. 24, 2016 /PRNewswire/ -- Amgen (Nasdaq: AMGN) today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter for the New Drug Application (NDA) for Parsabiv™ (etelcalcetide) for the treatment of secondary hyperparathyroidism (sHPT) in adult patients with chronic kidney disease (CKD) on hemodialysis. Amgen is reviewing the Complete Response Letter, and we anticipate a post-action meeting with the FDA later this year to discuss the Complete Response. The Complete Response Letter does not impact our regulatory submissions in other regions. ...
Source: Amgen News Release - August 25, 2016 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Elevated PTH With Normal Serum Calcium Level Elevated PTH With Normal Serum Calcium Level
What role do PTH measurements play in the assessment and management of normocalcaemic hyperparathyroidism?Clinical Endocrinology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 9, 2016 Category: Consumer Health News Tags: Diabetes & Endocrinology Journal Article Source Type: news

Managing Normocalcemic Primary HyperparathyroidismManaging Normocalcemic Primary Hyperparathyroidism
Find out about the appropriate management of patients with normocalcemic primary hyperparathyroidism. Endocrine Practice (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 28, 2016 Category: Consumer Health News Tags: Diabetes & Endocrinology Journal Article Source Type: news

Rayaldee Approved by FDA for Secondary HyperparathyroidismRayaldee Approved by FDA for Secondary Hyperparathyroidism
The FDA has approved calcifediol (Rayaldee, Opko Health, Inc) for the treatment of adults with secondary hyperparathyroidism associated with vitamin D insufficiency in stage 3 to 4 CKD. FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 21, 2016 Category: Consumer Health News Tags: Nephrology News Alert Source Type: news

FDA Approves Rayaldee (calcifediol) to Treat Secondary Hyperparathyroidism in Patients with Chronic Kidney Disease
MIAMI--(BUSINESS WIRE) June 21, 2016 -- OPKO Health, Inc. (NYSE:OPK) announced that the U.S. Food and Drug Administration (FDA) has approved Rayaldee (calcifediol) extended release capsules for the treatment of secondary hyperparathyroidism (SHPT)... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - June 21, 2016 Category: Drugs & Pharmacology Source Type: news

DiaSorin Webinar Details How to Define and Assess Parathyroid...
The Webinar, hosted by LabRoots, will discuss how the hormone is produced in the body, its role in bone and mineral metabolism, traits of primary and secondary hyperparathyroidism, and patient types...(PRWeb June 02, 2016)Read the full story at http://www.prweb.com/releases/2016/06/prweb13455035.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - June 2, 2016 Category: Pharmaceuticals Source Type: news

Billionaire's company inks $282 million deal with Swiss firm
Opko Health signed a $282 million deal with Vifor Fresenius Medical Care Renal Pharma (VFMCRP) to commercialize its Rayaldee drug candidate in certain international markets. The Miami-based biotech and pharmaceutical company (NYSE: OPK) led by billionaire Chairman and CEO Dr. Phillip Frost is developing Rayaldee to treat secondary hyperparathyroidism in patients with chronic kidney disease and vitamin D insufficiency. Opko granted Switzerland-based VFMCRP the rights to develop and commercialize… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - May 9, 2016 Category: Pharmaceuticals Authors: Brian Bandell Source Type: news

Surgery for PHPT improves sleep quality
BALTIMORE – Research into how primary hyperparathyroidism and parathyroidectomy affect sleep quality has been limited, but investigators at the Medical College of Wisconsin, Milwaukee, reported that... (Source: Clinical Endocrinology News)
Source: Clinical Endocrinology News - April 24, 2016 Category: Endocrinology Source Type: news

Surgery for PHPT improves sleep quality
BALTIMORE – Research into how primary hyperparathyroidism and parathyroidectomy affect sleep quality has been limited, but investigators at the Medical College of Wisconsin, Milwaukee, reported that... (Source: Clinical Neurology News)
Source: Clinical Neurology News - April 24, 2016 Category: Neurology Source Type: news

Surgery for PHPT improves sleep quality
BALTIMORE – Research into how primary hyperparathyroidism and parathyroidectomy affect sleep quality has been limited, but investigators at the Medical College of Wisconsin, Milwaukee, reported that... (Source: Family Practice News)
Source: Family Practice News - April 24, 2016 Category: Primary Care Source Type: news

Post-parathyroidectomy follow-up may need to be open-ended
BALTIMORE – Patients who have had parathyroidectomy for primary hyperparathyroidism can have disease recurrence 10 years or longer after surgery, raising the possibility that postop follow-up should... (Source: Clinical Endocrinology News)
Source: Clinical Endocrinology News - April 23, 2016 Category: Endocrinology Source Type: news

Negative sestamibi scan for primary hyperparathyroidism can mean no referral or surgery
BALTIMORE – In the treatment of primary hyperparathyroidism, clinical guidelines recommend using sestamibi scan for localizing adenoma, but increasingly endocrinologists are using sestamibi results... (Source: Clinical Endocrinology News)
Source: Clinical Endocrinology News - April 23, 2016 Category: Endocrinology Source Type: news

Surgery Best to Reduce Fractures in HyperparathyroidismSurgery Best to Reduce Fractures in Hyperparathyroidism
Surgically removing the tumor significantly reduces fracture risk over time in primary hyperparathyroidism, whereas bisphosphonate therapy increases fracture risk despite improving bone-mineral density. Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - April 7, 2016 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news

Surgery more effective than drugs for hyperparathyroidism
Stephen FellerLOS ANGELES, April 5 (UPI) -- Treating hyperparathyroidism, a cause of osteoporosis, with bisphosphonate drugs increases risk for bone fracture rather than reducing it, researchers found. (Source: Health News - UPI.com)
Source: Health News - UPI.com - April 5, 2016 Category: Consumer Health News Source Type: news

For treating a leading cause of osteoporosis, surgery is better than widely used medications
While most cases of osteoporosis are caused by normal aging, another leading cause of the bone-loss disease is a condition called hyperparathyroidism, in which the parathyroid glands release an excessive amount of a hormone that regulates the body’s calcium levels. Doctors commonly treat hyperparathyroidism using a class of prescription drugs called bisphosphonates, including alendronate (marketed under the brand name Fosamax) and ibandronate (Boniva), which are supposed to strengthen bones. Now, a study led by scientists at UCLA found that those drugs actually increase the risk of fracture, meaning that taking them ...
Source: UCLA Newsroom: Health Sciences - April 5, 2016 Category: Universities & Medical Training Source Type: news